Corcept Therapeutics (CORT) Fundamental Analysis: Revenue, Earnings & Valuation

2.86 / 10

Underperform

CORT's fundamental score is 2.9/10, reflecting a challenging profile. Key weaknesses include Days Sales Outstanding at 29.8 days (moderate collection speed) and Interest Coverage Ratio at 15.5x (adequate but not strong). Revenue growth YoY is 13.4%, which is positive yet unimpressive. Profitability metrics such as Profit-MV (-0.81) and Net income-Revenue (-0.43) are negative, indicating room for improvement. Asset and cash metrics also lag, while PB-ROE (9.60) is high, suggesting valuation may be stretched. Overall, the fundamental stance is subdued and underperform.

Analysis Checks(5/10)

Revenue-MV

Value-1.47

Score1/3

Weight11.01%

1M Return4.24%

Total operating revenue (YoY growth rate %)

Value13.41

Score1/3

Weight-1.60%

1M Return-0.79%

Days sales outstanding

Value29.84

Score2/3

Weight2.38%

1M Return1.10%

Profit-MV

Value-0.81

Score2/3

Weight21.87%

1M Return8.45%

Net income-Revenue

Value-0.43

Score3/3

Weight26.02%

1M Return9.29%

PB-ROE

Value9.60

Score0/3

Weight6.53%

1M Return2.72%

Interest coverage ratio (EBIT / Interest expense) (%)

Value15.48

Score2/3

Weight-2.19%

1M Return-1.11%

Operating revenue (YoY growth rate %)

Value13.41

Score1/3

Weight-1.54%

1M Return-0.76%

Asset-MV

Value-0.50

Score1/3

Weight16.00%

1M Return6.68%

Cash-MV

Value-1.31

Score2/3

Weight21.51%

1M Return8.41%

Is CORT undervalued or overvalued?

CORT scores 2.86/10 on fundamentals and holds a Premium valuation at present. Backed by its 11.33% ROE, 14.32% net margin, 41.04 P/E ratio, 6.80 P/B ratio, and -26.47% earnings growth, these metrics solidify its Underperform investment rating.